Immune Checkpoint Inhibitors-induced Thyroid Dysfunction in Patients with Advanced Malignancies

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

Latif Muhammad Farooq; Abdelgadir Elamin; Omara Mohamed; Rashid Fauzia; Tirmazy Syed H.; Khan Faraz; El Khoury Maroun; Bashier Alaaeldin; Alawadi Fatheya; Das Kaltar; Kumar Susheel; Basit Abdul Q.; El Shourbagy Dalia; Hamza Dina; Azam Faisal

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: MIDDLE EAST JOURNAL OF CANCER Year:2022 | Volume:13 | Issue:4 Page(s): 616-623

Download Full-Text

View:

Download:

Cites:

Information Journal Paper

Title

Immune Checkpoint Inhibitors-induced Thyroid Dysfunction in Patients with Advanced Malignancies

Author(s)

Keywords

immunotherapy

Hypothyroidism

Malignancy

Abstract

Background: Immune checkpoint inhibitors (ICIs), including antiprogrammed cell death receptor-1, antiprogrammed cell death ligand-1, and anticytotoxic T-lymphocyte-antigen 4, have improved patients’ outcome in advanced malignancies. These agents are associated with immune-related adverse events, including skin toxicity, gastrointestinal toxicity, hepatotoxicity, renal toxicities, and endocrinopathies.Method: We retrospectively reviewed the electronic medical records of patients treated with ICIs for advanced malignancies from two tertiary cancer care centers in the Emirate of Dubai, United Arab Emirates (UAE), including Dubai Hospital and American Hospital from November 2015 to January 2019. The patients were identified through the hospital cancer registry. We retrospectively collected data regarding the subjects’ demographics, cancer type, type of ICIs, thyroid-related adverse events, and duration of treatment.Results: In the present paper, 43 patients received ICI and 19 (44%) developed thyroid dysfunctions. The median age of ICI-receiving subjects was 60 (27-80) years; 26 of them were male and 17 were female. Pembrolizumab was the most used agent (42%). Pretreatment thyroid functions were normal for all the patients. Following treatment initiation, 19 (44%) patients developed thyroid abnormalities, including overt Hypothyroidism (n = 11, 57%), overt hyperthyroidism (n = 2, 11%), subclinical Hypothyroidism (n = 4, 21%), and subclinical hyperthyroidism (n = 2, 11%). Thyroid abnormalities developed in 56% of them treated with Pembrolizumab and 37% treated with Nivolumab.Conclusion: Hypothyroidism was the most prevalent thyroid adverse event in the patients treated with ICIs in our study and the majority of thyroid dysfunction encounters took place in the first 6 weeks after ICI initiation. The treatment was well tolerated and there were no treatment-related discontinuations or deaths.

Multimedia

No record.

Cites

No record.

References

No record.

Cite

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans